REG - Shield Therapeutics - Results of 2023 Annual General Meeting

Shield TherapeuticsAnnouncement

28/06/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230628:nRSb2911Ea&default-theme=true

RNS Number : 2911E  Shield Therapeutics PLC  28 June 2023

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Results of 2023 Annual General Meeting

 

London, UK, 28 June 2023: Shield Therapeutics plc (LSE: STX), a commercial
stage, pharmaceutical company with a focus on addressing iron deficiency with
its lead product Accrufer®/ Feraccru® (ferric maltol), announces the results
of the voting for each of the resolutions as set out in the Notice of Annual
General Meeting 2023. The Board reports that resolutions 1 to 10 passed as
ordinary resolutions and resolutions 11 and 12 were passed as special
resolutions, full details are shown below.

 

The following table shows the votes cast on each resolution:

 

                VOTES        %       VOTES AGAINST  %       WITHHELD VOTES

FOR
 Resolution 1   119,538,439  98.78%  1,475,717      1.22%   77,639
 Resolution 2   104,595,075  86.45%  16,390,220     13.55%  106,500
 Resolution 3   119,472,808  98.75%  1,512,487      1.25%   106,500
 Resolution 4   118,885,249  98.26%  2,100,046      1.74%   106,500
 Resolution 5   119,959,907  99.15%  1,025,388      0.85%   106,500
 Resolution 6   120,578,657  99.66%  407,538        0.34%   105,600
 Resolution 7   119,046,402  98.40%  1,938,893      1.60%   106,500
 Resolution 8   120,575,411  99.64%  437,845        0.36%   78,539
 Resolution 9   119,859,760  99.06%  1,143,185      0.94%   88,850
 Resolution 10  118,585,474  97.99%  2,433,532      2.01%   72,789
 Resolution 11  117,131,887  96.78%  3,892,308      3.22%   67,600
 Resolution 12  116,917,813  96.61%  4,106,382      3.39%   67,600

 

Notes:

1.    Number of shares in issue 713,036,342.

2. Details of the votes received on the resolutions are available on the
Company's website: https://www.shieldtherapeutics.com/corporate-documents/
(https://www.shieldtherapeutics.com/corporate-documents/) .

3.    Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                         www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                               +44 (0) 191 511 8500
 Hans-Peter Rudolf, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Oliver Duckworth                                                                    +44 (0)20 7418 8900

 Joint Broker

 finnCap Ltd

 Geoff Nash/ George Dollemore/Alice Lane/Nigel                                                   +44 (0)20 7220 0500
 Birks

 Financial PR & IR Advisor
 Walbrook PR
 Lianne Applegarth/Alice Woodings                                                                +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 John Mullaly                                                                                    +1 617 429 3548 or jmullaly@lifesciadvisors.com

 

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral
therapy for adults with iron deficiency, with or without anemia.
Accrufer®/Feraccru® has a novel mechanism of action compared to other oral
iron therapies and has been shown to be an efficacious and well-tolerated
therapy in a range of clinical trials. More information about
Accrufer®/Feraccru®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com)

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric
maltol). The Group has launched Accrufer® in the US and Feraccru® is
commercialized in the UK and European Union by Norgine B.V., who also have the
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialization of Accrufer® / Feraccru® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea,
and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGZZGZVVRMGFZM